Pfizer's Drug Distribution Deal Raises Concerns

Law360, New York (December 13, 2007, 12:00 AM EST) -- The United Kingdom’s competition regulator has revealed that exclusive drug distribution deals, like the one between Pfizer Inc. and Alliance Boots Plc, may potentially cost the country’s nationalized health service hundreds of millions of pounds.

A market study released by the Office of Fair Trading on Tuesday said that in addition to the increased cost, such direct-to-pharmacy schemes could also affect pharmacies and patients by creating longer wait times for drugs. The OFT is still concerned that the deals may have long-term effects on competition in...
To view the full article, register now.